Prevalence of HPV infection among HIV‑positive and HIV‑negative women in Central/Eastern Italy: 
Strategies of prevention

Tartaglia,Edoardo; Falasca,Katia; Vecchiet,Jacopo; Sabusco,Giovanna  Paola; Picciano,Giovanna; Di Marco,Roberto; Ucciferri,Claudio

doi:10.3892/ol.2017.7140

Prevalence of HPV infection among HIV‑positive and HIV‑negative women in Central/Eastern Italy: Strategies of prevention

Authors:
- Edoardo Tartaglia
- Katia Falasca
- Jacopo Vecchiet
- Giovanna Paola Sabusco
- Giovanna Picciano
- Roberto Di Marco
- Claudio Ucciferri
View Affiliations

Affiliations: Department of Medicine and Health Sciences ‘Vincenzo Tiberio’, University of Molise, I‑86100 Campobasso, Italy, Department of Medicine and Science of Aging‑Clinic of Infectious Diseases, University ‘G.’ d'Annunzio Chieti‑Pescara, I‑66100 Chieti, Italy, Department of Gynecology and Obstetrics, Cardarelli Hospital, I‑86100 Campobasso, Italy
Published online on: October 5, 2017 https://doi.org/10.3892/ol.2017.7140
Pages: 7629-7635

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present cross‑sectional‑study aimed to determine the prevalence of human papillomavirus (HPV)‑genotypes among human immunodeficiency virus (HIV)‑positive and ‑negative women in Central/Eastern Italy, and to identify the optimal strategies for effective HPV‑prevention in each group. A representative sample of HIV‑negative (150/200) and ‑positive (50/200) women, who underwent cervico‑vaginal‑swabbing. Swabs were analysed for a cytological screening and for a HPV‑DNA‑genotyping‑test. A total of 66/200 swabs resulted HPV‑positive. The overall HPV‑prevalence was 33% with a higher prevalence in the HIV‑positive‑group (48%) compared with the HIV‑negative‑group (28%). The most frequent genotypes were: 16, 31, 52, 58, 66, 73 and 89. Furthermore, the prevalence of specific genotypes was different in each group. The results of the present study indicate that HIV infection appears to be an independent risk factor for HPV‑infection. In addition, HPV‑infection is more common and more likely to persist in HIV‑positive compared with in HIV‑negative women. The optimal way to counteract HPV infection is through primary prevention. The stage of immunity (cluster of differentiation 4‑level) at the time of the HPV‑screening is one of the most important parameters for detection of susceptibility to HPV‑infection and to evaluate the response to the HPV‑vaccine in HIV‑positive women. It may be used to determine the sub‑group of HIV‑positive women that are more prone to HPV‑infections or that exhibit a partial response to the HPV‑vaccine. At present, a novel type of vaccine with 9‑genotypes is available and in the near future, it may serve an essential role in the prevention of HPV infections.

View Figures

View References

1	Lazarczyk M, Cassonnet P, Pons C, Jacob Y and Favre M: The EVER proteins as a natural barrier against papillomaviruses: A new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev. 73:348–370. 2009. View Article : Google Scholar : PubMed/NCBI
2	Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H and de Villiers EM: Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 401:70–79. 2010. View Article : Google Scholar : PubMed/NCBI
3	de Villiers EM: Cross-roads in the classification of papillomaviruses. Virology. 445:2–10. 2013. View Article : Google Scholar : PubMed/NCBI
4	McKenzie ND, Kobetz EN, Ganjei-Azar P, Rosa-Cunha I, Potter JE, Morishita A, Lucci JA III, Guettouche T, Hnatyszyn JH and Koru-Sengul T: HPV in HIV-infected women: Implications for primary prevention. Front Oncol. 4:1792014. View Article : Google Scholar : PubMed/NCBI
5	Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS and Markowitz LE: Prevalence of HPV infection among females in the United States. JAMA. 297:813–819. 2007. View Article : Google Scholar : PubMed/NCBI
6	Tartaglia E, Iafusco D, Galderisi A and Mastrantonio P: Do HPV vaccine genotypes agree with HPV circulating types? Lancet Infect Dis. 11:585–586. 2011. View Article : Google Scholar : PubMed/NCBI
7	Tartaglia E, Iafusco D, Cocca A, Palomba S, Rotondi M and Mastrantonio P: HPV at the time of Vaccine: Has screening reached its goal? Eur J Gynecol Oncol. 33:591–597. 2012.
8	Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Désy M and Rohan TE: Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 180:1415–1423. 1999. View Article : Google Scholar : PubMed/NCBI
9	Mbulawa ZZ, Marais DJ, Johnson LF, Coetzee D and Williamson AL: Impact of human immunodeficiency virus on the natural history of human papillomavirus genital infection in South African men and women. J Infect Dis. 206:15–27. 2012. View Article : Google Scholar : PubMed/NCBI
10	Lissouba P, Van de Perre P and Auvert B: Association of genital human papillomavirus infection with HIV acquisition: A systematic review and meta-analysis. Sex Transm Infect. 89:350–356. 2013. View Article : Google Scholar : PubMed/NCBI
11	Filia A: Epidemiological aspects of HPV infection. (last revision Apr 1, 2015). http://www.epicentro.iss.it/problemi/hpv/epid.aspFeb 23–2015
12	Madeddu G, Mameli G, Capobianco G, Babudieri S, Maida I, Bagella P, Rocca G, Cherchi PL, Sechi LA, Zanetti S, et al: HPV infection in HIV-positive females: The need for cervical cancer screening including HPV-DNA detection despite successful HAART. Eur Rev Med Pharmacol Sci. 18:1277–1285. 2014.PubMed/NCBI
13	Clifford GM, Goncalves MA and Franceschi S: HPV and HIV Study Group: Human papillomavirus types among women infected with HIV: A meta-analysis. AIDS. 20:2337–2344. 2006. View Article : Google Scholar : PubMed/NCBI
14	Camargo M, Soto-De Leon SC, Munoz M, Sanchez R, Peña-Herrera D, Pineda-Peña AC, Sussmann O, Paez C, Perez-Prados A, Patarroyo ME and Patarroyo MA: Human papillomavirus detection in women with and without human immunodeficiency virus infection in Colombia. BMC Cancer. 14:4512014. View Article : Google Scholar : PubMed/NCBI
15	Muñoz N, Castellsagué X, de González AB and Gissmann L: HPV in the etiology of human cancer. Vaccine. 24 Suppl 3:S3/1–10. 2006. View Article : Google Scholar
16	Calvo M, Laguno M, Martínez M and Martínez E: Effects of tobacco smoking on HIV-infected individuals. AIDS Rev. 17:47–55. 2015.PubMed/NCBI
17	Cotton SC, Sharp L, Seth R, Masson LF, Little J, Cruickshank ME, Neal K and Waugh N: TOMBOLA Group: Lifestyle and socio-demographic factors associated with high-risk HPV infection in UK women. Br J Cancer. 97:133–139. 2007. View Article : Google Scholar : PubMed/NCBI
18	Green J, de Gonzalez Berrington A, Smith JS, Franceschi S, Appleby P, Plummer M and Beral V: Human papillomavirus infection and use of oral contraceptives. Br J Cancer. 88:1713–1720. 2003. View Article : Google Scholar : PubMed/NCBI
19	Silva Ld, Miranda A, Batalha R, Ferreira L, Santos M and Talhari S: High-risk human papillomavirus and cervical lesions among women living with HIV/AIDS in Brazilian Amazon, Brazil. Braz J Infect Dis. 19:557–562. 2015. View Article : Google Scholar : PubMed/NCBI
20	Denny LA, Franceschi S, de Sanjosé S, Heard I, Moscicki AB and Palefsky J: Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine. 30 Suppl 5:F168–F174. 2012. View Article : Google Scholar : PubMed/NCBI
21	Rositch AF, Gravitt PE, Tobian AA, Newell K, Quinn TC, Serwadda D, Ssebbowa P, Kiggundu V, Gray RH and Reynolds SJ: Frequent detection of HPV before and after initiation of antiretroviral therapy among HIV/HSV-2 co-infected women in Uganda. PLoS One. 8:e553832013. View Article : Google Scholar : PubMed/NCBI
22	Hong H, He TF, Ni HX, Zhang S and Xu GZ: Prevalence and genotype distribution of HPV infection among women in Ningbo, China. Int J Gynaecol Obstet. 131:96–99. 2015. View Article : Google Scholar : PubMed/NCBI
23	Sammarco ML, Ucciferri C, Tamburro M, Falasca K, Ripabelli G and Vecchiet J: High prevalence of human papillomavirus type 58 in HIV infected men who have sex with men: A preliminary report in Central Italy. J Med Virol. 88:911–914. 2016. View Article : Google Scholar : PubMed/NCBI
24	Liu G, Markowitz LE, Hariri S, Panicker G and Unger ER: Seroprevalence of 9 human papillomavirus types in the United States, 2005–2006. J Infect Dis. 213:191–198. 2016. View Article : Google Scholar : PubMed/NCBI
25	Petrosky E, Bocchini JA Jr, Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER and Markowitz LE: Centers for Disease Control and Prevention (CDC): Use of 9-valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 64:300–304. 2015.PubMed/NCBI
26	Chesson HW, Laprise JF, Brisson M and Markowitz LE: Impact and cost-effectiveness of 3 doses of 9-Valent human papillomavirus (HPV) vaccine among US females previously vaccinated with 4-valent HPV vaccine. J Infect Dis. 213:1694–1700. 2016. View Article : Google Scholar : PubMed/NCBI
27	Brisson M, Laprise JF, Chesson HW, Drolet M, Malagón T, Boily MC and Markowitz LE: Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States. J Natl Cancer Inst. 108:pii: djv282. 2015.PubMed/NCBI
28	Kojic EM, Rana AI and Cu-Uyin S: Human papillomavirus vaccination in HIV-infected women: Need for increased coverage. Expert Rev Vaccines. 15:105–117. 2016. View Article : Google Scholar : PubMed/NCBI
29	Zhai L and Tumban E: Gardasil-9: A global survey of projected efficacy. Antiviral Res. 130:101–109. 2016. View Article : Google Scholar : PubMed/NCBI